Elanco/$ELAN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Elanco

Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.

Ticker

$ELAN

Primary listing

NYSE

Industry

Pharmaceuticals

Employees

9,225

ISIN

US28414H1032

Elanco Metrics

BasicAdvanced
$7.1B
19.08
$0.75
1.50
-

What the Analysts think about Elanco

Analyst ratings (Buy, Hold, Sell) for Elanco stock.

Bulls say / Bears say

Elanco's approval of Bovaer positions the company to capitalize on the growing demand for sustainable livestock solutions, potentially tapping into a market worth $1-2 billion. (Investing.com)
The company's robust pipeline includes six potential blockbuster products slated for launch in 2024 and 2025, indicating strong future growth prospects. (Seeking Alpha)
Elanco has made significant progress in paying down debt following its acquisition of Bayer Animal Health in 2020, improving its financial stability. (Seeking Alpha)
The inclusion of a boxed warning on Zenrelia's label may limit its market adoption, as veterinarians and pet owners could be hesitant to use a product with prominent safety concerns. (Investing.com)
Elanco faces intense competition from established players like Zoetis, which could challenge its market share and growth in the animal health industry. (Investing.com)
Recent pipeline setbacks and product delays have dampened investor sentiment, potentially affecting Elanco's ability to aggressively market and promote new offerings. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.

Elanco Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Elanco Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ELAN

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs